MedTrace Logo

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

NCT00003991 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2013-11-06

No results posted yet for this study

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission.

PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy.

Conditions

Interventions

BIOLOGICAL

aldesleukin

DRUG

histamine dihydrochloride

Sponsors & Collaborators

  • Maxim Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Barbara Berryhill · Maxim Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-07-31
Completion
2011-08-31

Countries

  • United States
  • Australia
  • Canada
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Israel
  • New Zealand
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003991 on ClinicalTrials.gov